Article By:
ChinaBio® Today
Saturday, August 14, 2021 1:30 PM EDT
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to $2.4 billion in milestones.
This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar
Oh man, sorry to hear about your cancer Brett Hershman.
Personally, I'd like to hear more about $DYAI.